UK cell therapy company Cell Mogrify has been awarded £420,000 funding from Innovate UK to accelerate its data-driven cell conversion programmes. The funding from the UK’s innovation agency will be ...

CAMBRIDGE, England & BRISBANE, Calif.--(BUSINESS WIRE)--Mogrify Ltd (Mogrify ®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell ...

Mogrify Limited (Mogrify ®), a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, today announced it had secured the ...

Cell Mogrify (Mogrify), has been granted funding by the UK’s innovation agency, Innovate UK, to accelerate regenerative cell therapies. United Kingdom-based company, Cell Mogrify (Mogrify), has been ...

Acute myeloid leukaemia is a blood cancer characterised by blocked differentiation and increased proliferation of immature myeloid blasts in the bone marrow and peripheral blood. The differentiation ...

Mogrify Limited (Mogrify®), a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, has announced the ...

Mogrify Ltd (Mogrify), a UK company aiming to transform the development of life-saving cell therapies, today announced the initial close of its Series A funding. The Company raised $16 million USD in ...

(RTTNews) - Mogrify Limited and Astellas Pharma Inc. (ALPMY, ALPMY) have executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.

Cambridge, UK-based biotech startup Mogrify, which is working on systematizing the development of novel cell therapies in areas such as regenerative medicine, has closed an initial $16 million Series ...

Mogrify Limited (Mogrify®), a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, has announced the ...